Cingulate Inc., a Delaware corporation listed on the Nasdaq under the symbol 'CING', has filed a prospectus related to the offer and sale of up to 5,973,000 shares of common stock. These shares are issuable upon the exercise of various previously issued warrants, including pre-funded warrants, Series A and Series B common warrants, and placement agent warrants, as part of a public offering that closed on February 6, 2024. The exercise prices for these warrants range from $0.0001 to $2.50 per share, with expiration dates extending up to February 2, 2029. Cingulate will not sell any common stock in this offering and will not receive proceeds from the sale of the common stock covered by this prospectus. However, the company will receive proceeds from the exercise...Show More

Cingulate Inc., a Delaware corporation listed on the Nasdaq under the symbol 'CING', has filed a prospectus related to the offer and sale of up to 5,973,000 shares of common stock. These shares are issuable upon the exercise of various previously issued warrants, including pre-funded warrants, Series A and Series B common warrants, and placement agent warrants, as part of a public offering that closed on February 6, 2024. The exercise prices for these warrants range from $0.0001 to $2.50 per share, with expiration dates extending up to February 2, 2029. Cingulate will not sell any common stock in this offering and will not receive proceeds from the sale of the common stock covered by this prospectus. However, the company will receive proceeds from the exercise of the warrants if they are exercised for cash. The net proceeds from the sale of the common stock will go to the holders of the warrants. The funds received from the exercise of the warrants are intended for general working capital and other corporate purposes. Cingulate is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements. The company's last reported sale price of common stock on Nasdaq was $1.10 per share as of March 28, 2024.